Cargando…
Dogmas, challenges, and promises in phase III allergen immunotherapy studies()
The concept of treatment of an allergy with the offending allergen was introduced more than a century ago. Allergen immunotherapy (AIT) is the only disease modifying treatment of allergic diseases caused by inhalational allergens and insect venoms. Despite this, only few AIT products have reached li...
Autores principales: | De Kam, Pieter-Jan, Kramer, Matthias F., Shamji, Mohamed H., Oluwayi, Kemi, Heath, Matthew D., Jensen-Jarolim, Erika, Berger, Markus H., Berger, Uwe E., Graessel, Anke, Sellwood, Fiona, Zielen, Stefan, Vogelberg, Christian, Zieglmayer, Petra, Mösges, Ralph, Klimek, Ludger, DuBuske, Lawrence M., Shreffler, Wayne G., Bernstein, Jonathan A., Kündig, Thomas M., Skinner, Murray A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487954/ https://www.ncbi.nlm.nih.gov/pubmed/34659627 http://dx.doi.org/10.1016/j.waojou.2021.100578 |
Ejemplares similares
-
Authorised allergen products for intracutaneous testing may no longer be available in Germany: Allergy textbooks have to be re-written
por: Klimek, Ludger, et al.
Publicado: (2015) -
Real‐world evidence for the long‐term effect of allergen immunotherapy: Current status on database‐derived European studies
por: Vogelberg, Christian, et al.
Publicado: (2022) -
Is The Allergen Really Needed in Allergy Immunotherapy?
por: Kündig, Thomas M., et al.
Publicado: (2014) -
Allergen challenge tests in allergen immunotherapy: State of the art
por: Zieglmayer, Petra, et al.
Publicado: (2023) -
Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany
por: Brehler, Randolf, et al.
Publicado: (2016)